Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
DSGNthis companyDesign Therapeutics, Inc.	$10.55	-7.69×	2.53×	0×	-7.55×	-97.5%	0.0%	0.0%	0.0%	-32.8%	-37.1%	-10.1%	0.01×	0.22×	0×	17.14×	0.0%	1	26.54	2	C
DYNDyne Therapeutics, Inc.	$18.43	-5.64×	2.58×	0×	-3.74×	-61.0%	0.0%	0.0%	0.0%	-45.9%	-41.0%	-16.1%	0.02×	1.99×	-75.61×	22.25×	0.0%	2	3.6	2	C+
FULCFulcrum Therapeutics, Inc.	$3.70	-9.58×	2.05×	0×	-7.15×	-17.6%	0.0%	0.0%	0.0%	-21.5%	-23.8%	-8.4%	0.02×	2.6×	0×	27.4×	0.0%	2	10.2	3	B
IONSIonis Pharmaceuticals, Inc.	$28.90	-33.24×	25.88×	13.41×	-52.41×	-292.2%	98.3%	-40.5%	-40.4%	-77.9%	-12.0%	-2.5%	5.35×	-7.89×	-4.22×	3.83×	0.0%	2	0.89	1	D+
LRMRLarimar Therapeutics, Inc.	$2.46	-1.68×	3.56×	0×	-1.19×	-55.3%	0.0%	0.0%	0.0%	-212.2%	-210.0%	-40.8%	0.05×	0.49×	0×	2.19×	0.0%	1	-2.84	2	C+
PEPGPepGen Inc.	$2.47	-3.07×	1.86×	0×	-2.62×	-56.9%	0.0%	0.0%	0.0%	-60.8%	-56.9%	-29.8%	0.12×	0.49×	0×	11.94×	0.0%	2	-0.25	2	C+
Peer median	—	-5.64×	2.58×	0×	-3.74×	-56.9%	0.0%	0.0%	0.0%	-60.8%	-41.0%	-16.1%	0.05×	0.49×	0×	11.94×	0.0%	2	0.89	2	—